Elizabethkingia meningoseptica: Case report on an emerging pathogen and its associated treatment challenges
Abstract
Elizabethkingia meningoseptica is a Gram-negative bacillus that was previously thought to rarely infect humans but recently has been identified as an emerging pathogen in both community and nosocomial settings. Typically found in the environment, this organism has been shown to infect predisposed hosts with an immunocompromised status and/or a prolonged exposure to healthcare settings. Herein, we report a case of a 78-year-old male with newly diagnosed myelodysplastic syndrome initially admitted to the hospital with pneumonia and then re-admitted after discharge with septic shock and evidence of E. meningoseptica bacteremia isolated from blood cultures. Treatment with piperacillin-tazobactam was initiated and later escalated to dual-therapy with the addition of levofloxacin. After hemodynamic stability was achieved, the patient was discharged on oral levofloxacin to complete a 21-day course of therapy. E. meningoseptica displays a unique multi-drug resistant profile that often makes initial antimicrobial selection challenging. This case illustrates the importance of early detection and use of in vitro susceptibility testing to guide therapeutic decision-making in E. meningoseptica infections; a pathogen known to have both high morbidity and mortality particularly in the immunocompromised.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.